Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPLERAF: Eplerenone for prevention of atrial fibrillation recurrence after cardioversion
2007-002119-17Phase 2Active
- Sponsor
- Saarland University
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of eplerenone in Atrial fibrillation (AFib), sponsored by Saarland University. Primary endpoint: AF recurrence within 8 weeks. Started Aug 2007; status: active.
02
Drugs
eplerenone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-002119-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002119-17.